Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Breast Neoplasms × Patient Reported Outcome Measures × Clear all

Phase

Status

Unknown 1 Terminated 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 2 Thoracic Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Neoplasms by Site 1 Multiple Chronic Conditions 1 Lung Neoplasms 1 Lung Diseases 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Carcinoma, Bronchogenic 1 Bronchial Neoplasms 1 Breast Neoplasms 1

Interventions

Trastuzumab 66 Capecitabine 51 Cyclophosphamide 47 Docetaxel 45 Paclitaxel 44 Letrozole 38 Fulvestrant 34 Lapatinib 29 Carboplatin 28 Vinorelbine 27 Doxorubicin 27 Bevacizumab 26 Anastrozole 21 pembrolizumab 19 exemestane 19 Tamoxifen 18 Gemcitabine 18 Albumin-Bound Paclitaxel 18 Radiotherapy 17 Everolimus 14 Epirubicin 13 palbociclib 12 Taxes 12 pertuzumab 11 Ado-Trastuzumab Emtansine 11 130-nm albumin-bound paclitaxel 11 eribulin 10 atezolizumab 10 Surveys and Questionnaires 10 Magnetic Resonance Spectroscopy 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05932667 2023-12-21

DEMETER

Institut Curie

Phase 2 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡